The company may have more catalysts ahead Eli Lilly isn't done in developing new weight loss treatments. In fact, the best may still be to come, as it's working on a pill, which could be a game ...

And amid all that, Eli Lilly continues to grow its revenue at a faster pace than any of its comparable peers. In the first quarter, the company's revenue jumped by 45% year over year to $12.7 billion.

Eli Lilly has filed lawsuits against four telehealth companies—Mochi Health, Fella Health, Willow Health, and Henry Meds—accusing them of deceptively marketing and selling compounded versions ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years. 2.

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in ...

Eli Lilly is currently spending 21.6% of revenue on capital expenditures – metrics that were seen the last time in the early 1990s. Data by YCharts ...

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy Zepbound achieved average weight reduction of 20.2% compared to 13.7% with Wegovy, according to a study funded by Lilly ...

Key Points Visa, Netflix and Eli Lilly are moving closer to the trillion dollar club. While all three have the potential, one will reach $3 trillion sooner than the others.

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and delivered strong market performance -- so strong that detractors might ...